引用本文:陈浩然,孔令泉.乳腺癌靶向治疗相关心脏毒性防治的研究进展[J].中国临床新医学,0,():-.
chen hao ran,kong ling quan.乳腺癌靶向治疗相关心脏毒性防治的研究进展[J].中国临床新医学,0,():-.
【打印本页】   【下载PDF全文】   【查看/发表评论】  【EndNote】   【RefMan】   【BibTex】
过刊浏览    高级检索
本文已被：浏览 423次   下载 0次  
分享到： 微信 更多
字体:加大+|默认|缩小-
乳腺癌靶向治疗相关心脏毒性防治的研究进展
陈浩然,孔令泉
重庆医科大学附属第一医院内分泌乳腺外科
摘要:
随着靶向治疗被广泛用于人类表皮生长因子受体-2（human epidermal growth factor receptor-2，HER-2）+乳腺癌患者，其所带来的心脏毒性，比如：左室射血分数下降、充血性心力衰竭等，已成为限制其使用的主要原因。该文主要就抗HER-2治疗相关心脏毒性的发生现状、防治进展进行综述。
关键词:  乳腺癌  人类表皮生长因子受体-2  靶向治疗  心脏毒性
DOI：
分类号:
基金项目:
Advances in the prophylaxis and treatment of cardiotoxicity associated with targeted therapy of breast cancer
chen hao ran1,2, kong ling quan
1.Department of Endocrine&2.Breast Surgery, The First Affiliated Hospital of Chongqing Medical University
Abstract:
With the prevalence of targeted therapy in human epidermal growth factor receptor-2 (HER-2)+ breast cancer, its associated cardiotoxicity manifested as decline in left ventricular ejection fraction and congestive heart failure ect, has been the main reason for restricting its application. The prevalence of cardiotoxicity induced by anti-HER-2 therapy and its prophylactic & therapeutic advances are reviewed in this paper.
Key words:  braest cancer  human epidermal growth factor receptor-2  targeted therapy  cardiotoxicity